https://www.openbell.ai/ 2026-09-18T11:29:25.891Z hourly 1.0 https://www.openbell.ai/support 2026-09-18T11:29:25.891Z monthly 0.7 https://www.openbell.ai/privacy 2026-09-18T11:29:25.891Z monthly 0.5 https://www.openbell.ai/terms 2026-09-18T11:29:25.891Z monthly 0.5 https://www.openbell.ai/feed.json 2026-09-18T11:29:25.891Z hourly 0.8 https://www.openbell.ai/news/USO:1789730669066 2026-09-18T11:24:29.066Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Saudis Tell European Refiners They’ll Get No Crude Next Month' - Bloomberg Saudi Arabia has informed European refiners that they will not receive any crude oil shipments next month, a move that could significantly impact oil supply in the region. This decision follows the Kingdom's ongoing strategy to manage oil production levels amid fluctuating global demand. The announcement may lead to increased oil prices as refiners seek alternative sources to meet their needs. https://www.openbell.ai/news/TCRT:1789730654779 2026-09-18T11:24:14.779Z daily 0.9 https://cdn.brandfetch.io/TCRT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Market-Moving News for September 18th Alaunos Therapeutics (TCRT) filed a patent application for the identification of neoantigen-reactive T cell receptors, causing its stock to rise by 69%. DataMeds AI (MEDS) settled litigation related to outstanding debt and receivables, retiring approximately 364,099 shares and paying $450,000 in cash, resulting in a 24% increase in its stock price. Conversely, Xenon Pharmaceuticals (XENE) saw a 26% decline in its stock after announcing a temporary pause in the enrollment of new patients in ongoing psychiatry studies. https://www.openbell.ai/news/NGVC:1789730552096 2026-09-18T11:22:32.096Z daily 0.9 https://cdn.brandfetch.io/NGVC/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Initiates Coverage On Natural Grocers with Buy Rating, Announces Price Target of $35 B of A Securities analyst Vicky Liu has initiated coverage on Natural Grocers (NYSE: NGVC) with a Buy rating. The firm has set a price target of $35 for the stock. https://www.openbell.ai/news/ONON:1789730510965 2026-09-18T11:21:50.965Z daily 0.9 https://cdn.brandfetch.io/ONON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on On Holding, Maintains $37 Price Target Needham analyst Tom Nikic has reiterated a Buy rating on On Holding (NYSE: ONON) and maintained a price target of $37 for the stock. This endorsement reflects confidence in the company's performance and market position. https://www.openbell.ai/news/DKNG:1789730218482 2026-09-18T11:16:58.482Z daily 0.9 https://cdn.brandfetch.io/DKNG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on DraftKings, Maintains $35 Price Target Needham analyst Bernie McTernan has reiterated a Buy rating on DraftKings (NASDAQ: DKNG) and maintained a price target of $35. This endorsement reflects confidence in the company's performance and market position. https://www.openbell.ai/news/DKNG:1789729885688 2026-09-18T11:11:25.688Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/The-DraftKings-Trade.jpg?width=250&height=187 What's Going On With DraftKings Stock on Friday? DraftKings Inc. (NASDAQ: DKNG) shares rose 0.67% to $22.62 during Friday's premarket trading as investors reacted to NBA star LeBron James switching from DraftKings to Polymarket in a $15 million deal. The stock remains in a downtrend, trading significantly below key moving averages, with estimates for the upcoming earnings report on November 5, 2026, predicting a loss of 16 cents per share on revenue of $1.42 billion. Analysts maintain a Buy rating for DKNG, with an average price target of $34.14. https://www.openbell.ai/news/BLSM:1789729700070 2026-09-18T11:08:20.070Z daily 0.9 https://cdn.brandfetch.io/BLSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud BlossomHill Therapeutics Q2 EPS $(8.75) BlossomHill Therapeutics (NASDAQ: BLSM) reported a Q2 loss of $(8.75) per share, which represents a 58.8% increase in losses compared to $(5.51) per share in the same quarter last year. https://www.openbell.ai/news/TRUG:1789729665575 2026-09-18T11:07:45.575Z daily 0.9 https://cdn.brandfetch.io/TRUG/w/400/h/400?c=1idopYfmtR7ZKg8QMud TruGolf Links Announces Tokenized Equipment Leasing And Fractional Franchise Ownership Plans With Polymath, Contingent On Pending Acquisition Close openbell Financial News https://www.openbell.ai/news/SVAQ:1789729644577 2026-09-18T11:07:24.577Z daily 0.9 https://cdn.brandfetch.io/SVAQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud EigenQ Secures $45M Convertible Note Financing To Advance Commercialization Ahead Of SVAQ Merger EigenQ, Inc. has secured $45 million in convertible note financing to support its commercialization efforts ahead of its merger with Silicon Valley Acquisition Corp. (SVAQ). The financing includes an upfront funding of $22.5 million, with the remainder expected to be funded upon completion of the merger, which values the combined entity at an estimated $3 billion. The merger is anticipated to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals, and aims to enhance EigenQ's capital access while allowing existing shareholders to maintain significant ownership. https://www.openbell.ai/news/BSEM:1789729632891 2026-09-18T11:07:12.891Z daily 0.9 https://cdn.brandfetch.io/BSEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioStem Technologies Announces $40M Committed Equity Facility With Roth Principal Investments For Working Capital, General Corporate Purposes openbell Financial News https://www.openbell.ai/news/OKLO:1789729575526 2026-09-18T11:06:15.526Z daily 0.9 https://cdn.brandfetch.io/OKLO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Oklo Stock Gaining Friday? Oklo Inc. (NYSE: OKLO) stock rose 0.63% to $39.90 in premarket trading as investors showed renewed interest in nuclear power stocks following the U.S. House's passage of the Ratepayer Protection Act. This bill aims to manage rising electricity costs associated with increased demand from AI data centers, highlighting the potential for nuclear energy solutions. Despite the gain, Oklo's stock remains in a longer-term downtrend, trading below key moving averages, with a consensus Buy rating and an average price target of $85.46. https://www.openbell.ai/news/CATO:1789729547053 2026-09-18T11:05:47.053Z daily 0.9 https://cdn.brandfetch.io/CATO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cato Corporation To Close ~70 Additional Underperforming Stores In Q3 And Q4; Brings FY26 Total Planned Stores Closures To ~120; Sees $1M-$1.3M In Associated Costs Cato Corporation plans to close approximately 70 additional underperforming stores in Q3 and Q4, bringing the total planned store closures for FY26 to around 120. The company anticipates incurring costs between $1 million and $1.3 million associated with these closures, primarily for disposing of signage and fixtures. These closures are part of an annual review process of store performance, and the company expects that this strategy will positively impact operating results in fiscal 2027 and beyond. https://www.openbell.ai/news/OKLO:1789729519823 2026-09-18T11:05:19.823Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Konskie--Poland---August-03--2025-Oklo-C.jpg?width=250&height=187 Why Is Oklo Stock Gaining Friday? Oklo Inc. (NYSE: OKLO) stock rose 0.63% to $39.90 in premarket trading as investors showed renewed interest in nuclear power stocks following the U.S. House's passage of the Ratepayer Protection Act, which aims to mitigate rising electricity costs. The bill highlights the potential for nuclear and advanced reactor developers to supply reliable energy for AI data centers. Despite the gain, Oklo's stock remains in a longer-term downtrend, trading below several key moving averages, with a Buy consensus rating and an average price forecast of $85.46. https://www.openbell.ai/news/BRR:1789729448866 2026-09-18T11:04:08.866Z daily 0.9 https://cdn.brandfetch.io/BRR/w/400/h/400?c=1idopYfmtR7ZKg8QMud ProCap Financial To Join Russell 2000 And Russell 3000 Indexes, Effective September 21 ProCap Financial will be added to the Russell 2000 and Russell 3000 indexes effective September 21, 2026. The company has seen significant growth in its AI agent lab, Silvia, which has connected over $60 billion in assets and converted 25% of its monthly active users to paying subscribers since its launch in May 2025. Additionally, ProCap Financial will rename itself Silvia, Inc. and begin trading under the ticker 'SVIA' starting September 22, 2026. https://www.openbell.ai/news/MG:1789729361981 2026-09-18T11:02:41.981Z daily 0.9 https://cdn.brandfetch.io/MG/w/400/h/400?c=1idopYfmtR7ZKg8QMud MISTRAS Group Agrees To Be Acquired By Affiliates Of H.I.G. Capital In All-Cash Transaction, Representing Enterprise Value Of ~$866M, Including Outstanding Debt MISTRAS Group, Inc. has entered into a definitive agreement to be acquired by affiliates of H.I.G. Capital in an all-cash transaction valued at approximately $866 million, including outstanding debt. Stockholders will receive $20.35 per share, representing an 8% and 13% premium to the Company’s 30 and 90-day average share prices, respectively. The transaction has been unanimously approved by MISTRAS's Board of Directors and is expected to close in late 2026 or early 2027, pending stockholder and regulatory approvals. A 40-day 'go-shop' period is in place for alternative acquisition proposals. https://www.openbell.ai/news/MU:1789729332507 2026-09-18T11:02:12.507Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud What's Going On With Micron Technology Stock Friday? Micron Technology Inc. (NASDAQ: MU) stock rose 1.23% to $989.50 in premarket trading, continuing a strong performance with a 478.78% increase over the past year. The company is expanding U.S. memory production with new facilities in Boise, Idaho, and Clay, New York, amid a global supply shortage. Analysts maintain a Buy consensus rating, with an average price forecast of $1,521.74, although some have adjusted their forecasts lower. The stock is currently trading above its 20-day, 50-day, and 200-day moving averages, indicating a long-term uptrend. https://www.openbell.ai/news/MU:1789729323487 2026-09-18T11:02:03.487Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud What's Going On With Micron Technology Stock Friday? Micron Technology Inc. (NASDAQ: MU) stock increased by 1.23% to $989.50 in premarket trading, benefiting from a stronger technology sector. Over the past year, Micron shares have surged 478.78%, and the company is set to release its earnings report on September 30. Micron is expanding its U.S. memory production with new facilities in Boise, Idaho, and Clay, New York, amid a global supply shortage, although the industry faces a potential shortage of skilled workers. Analysts maintain a Buy consensus rating with price forecasts ranging from $1,150 to $1,521.74. https://www.openbell.ai/news/CAVA:1789729271141 2026-09-18T11:01:11.141Z daily 0.9 https://cdn.brandfetch.io/CAVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud CAVA Group Board Approves $100M Share Repurchase Program CAVA Group, Inc. has announced a $100 million share repurchase program approved by its board of directors. The program allows for repurchases in the open market or through privately negotiated transactions, with flexibility in timing and amount based on market conditions. It is set to expire on September 17, 2027, and will be funded through existing cash and operational cash flows. https://www.openbell.ai/news/MU:1789729255814 2026-09-18T11:00:55.814Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Los-Angeles--California---24-January-202.jpg?width=250&height=187 What's Going On With Micron Technology Stock Friday? Micron Technology Inc. (NASDAQ: MU) saw its stock rise 1.23% to $989.50 in premarket trading, benefiting from a positive technology sector backdrop. Over the past year, Micron's shares have surged 478.78%, and the company is preparing for its earnings report on September 30. Additionally, Micron is expanding its U.S. production capabilities with new facilities in Boise, Idaho, and Clay, New York, amid a global memory supply shortage, although the industry faces a potential shortage of skilled workers. Analysts maintain a Buy consensus rating for Micron, with an average price forecast of $1,521.74. https://www.openbell.ai/news/MTN:1789729092037 2026-09-18T10:58:12.037Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Konskie--Poland---March-01--2025-Vail-Re.jpg?width=250&height=187 Vail Resorts Likely To Report Q4 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Vail Resorts, Inc. (NYSE: MTN) is expected to report a quarterly loss of $5.25 per share for Q4, compared to a loss of $5.08 per share in the same period last year. The consensus revenue estimate is $273.16 million, slightly up from $271.29 million reported last year. Shares of Vail Resorts fell 1.7% to close at $137.76 on Thursday. Recent analyst ratings show a mix of maintained and adjusted price targets, with JP Morgan raising its target to $126 and Truist cutting it to $195. https://www.openbell.ai/news/MRK:1789729067695 2026-09-18T10:57:47.695Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Merck's KEYTRUDA in combination with Padcev for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC). This recommendation is based on positive results from the Phase 3 KEYNOTE-B15 trial, which showed improvements in event-free survival, overall survival, and pathologic complete response rates. If approved, this regimen would be the first PD-1 inhibitor plus antibody-drug conjugate treatment for MIBC patients in the EU, with a final decision from the European Commission expected by the fourth quarter of 2026. https://www.openbell.ai/news/NVO:1789728950739 2026-09-18T10:55:50.739Z daily 0.9 https://cdn.brandfetch.io/NVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud CHMP of the European Medicines Agency Recommends Approving Novo Nordisk's Once-Weekly Sogroya for Children with Idiopathic Short Stature with Persistent Growth Disturbance The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended Novo Nordisk's once-weekly Sogroya (somapacitan) for children with idiopathic short stature (ISS) with persistent growth disturbance. If approved, Sogroya would be the first growth hormone treatment for ISS in the EU, following a previous recommendation for its use in children born small for gestational age and with Noonan Syndrome. The European Commission's decision on marketing authorization is expected later this year. https://www.openbell.ai/news/OCS:1789728798162 2026-09-18T10:53:18.162Z daily 0.9 https://cdn.brandfetch.io/OCS/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39 HC Wainwright & Co. analyst Yi Chen has maintained a 'Buy' rating on Oculis Holding (NASDAQ: OCS) and increased the price target from $26 to $39. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/RHHBY:1789728670357 2026-09-18T10:51:10.357Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis Roche has received a positive recommendation from the EMA's CHMP for its drug Ocrevus, aimed at pediatric patients with relapsing forms of multiple sclerosis (MS). This follows the U.S. FDA's approval in May 2026, and a final decision from the European Commission is anticipated soon. The recommendation is based on the Phase III OPERETTA 2 study, which demonstrated that Ocrevus reduced the risk of relapses by 48% compared to the current standard treatment, fingolimod, while also showing significant reductions in brain inflammation. Approximately 40,000 children and adolescents are affected by MS globally, highlighting the importance of this treatment option. https://www.openbell.ai/news/AMD:1789728599133 2026-09-18T10:49:59.133Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud AMD Says AI Adoption Is Still Early, Sees No Slowdown in Demand Advanced Micro Devices Inc. (AMD) reported a nearly 1% increase in stock price during premarket trading, attributed to positive comments from CTO Mark Papermaster regarding ongoing demand for artificial intelligence (AI). Papermaster indicated that businesses are still in the early stages of AI adoption and while they may become more selective with workloads, overall demand is not expected to decline. AMD is transitioning from being a chip provider to a solution provider, planning to introduce AI rack-level integration later this year to capitalize on AI infrastructure spending. https://www.openbell.ai/news/SKHY:1789728594772 2026-09-18T10:49:54.772Z daily 0.9 https://cdn.brandfetch.io/SKHY/w/400/h/400?c=1idopYfmtR7ZKg8QMud SK hynix’s Solidigm Eyes New York for US Chip Factory SK hynix's subsidiary Solidigm is considering establishing a NAND flash memory factory in upstate New York, which could enhance its competitiveness and reduce reliance on its current facility in Dalian, China. The potential investment aligns with U.S. government efforts to boost domestic chip manufacturing amid rising demand for artificial intelligence infrastructure. SK hynix shares rose 1.44% to $185.62 in premarket trading, and the stock carries a consensus Buy rating with an average price forecast of $247.67. https://www.openbell.ai/news/SKHY:1789728546588 2026-09-18T10:49:06.588Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/The-Sk-Hynix-Logo.jpg?width=250&height=187 SK hynix’s Solidigm Eyes New York for US Chip Factory SK hynix's subsidiary Solidigm is considering establishing a NAND flash memory factory in upstate New York, as reported by Reuters. This potential investment aligns with U.S. government efforts to boost domestic chip manufacturing amid rising demand for artificial intelligence infrastructure. SK hynix shares rose 1.44% to $185.62 in premarket trading, and the stock carries a consensus Buy rating with an average price forecast of $247.67. https://www.openbell.ai/news/AMD:1789728542316 2026-09-18T10:49:02.316Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud AMD Says AI Adoption Is Still Early, Sees No Slowdown in Demand Advanced Micro Devices Inc. (AMD) reported a nearly 1% increase in stock price during premarket trading, attributed to positive remarks from CTO Mark Papermaster regarding ongoing demand for artificial intelligence (AI). Papermaster indicated that while businesses are still in the early stages of AI adoption, they are not expected to slow overall demand despite becoming more selective with workloads. AMD is transitioning from a chip provider to a solution provider, planning to introduce AI rack-level integration later this year, which could enhance its exposure to AI infrastructure spending. https://www.openbell.ai/news/AMD:1789728533749 2026-09-18T10:48:53.749Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Amd-Chip-On-A-Dark--Intricate-Circuit-Bo.jpg?width=250&height=187 AMD Says AI Adoption Is Still Early, Sees No Slowdown in Demand Advanced Micro Devices Inc. (AMD) stock increased by nearly 1% in premarket trading, following positive remarks from CTO Mark Papermaster regarding ongoing demand for artificial intelligence (AI). Papermaster indicated that while businesses are still in the early stages of AI adoption, they do not expect a slowdown in demand, as companies seek productivity gains. AMD is also transitioning from being a chip provider to a solution provider, planning to introduce AI rack-level integration later this year, which could enhance its exposure to AI infrastructure spending. https://www.openbell.ai/news/SKHY:1789728531682 2026-09-18T10:48:51.682Z daily 0.9 https://cdn.brandfetch.io/SKHY/w/400/h/400?c=1idopYfmtR7ZKg8QMud SK hynix’s Solidigm Eyes New York for US Chip Factory SK hynix's subsidiary Solidigm is considering establishing a NAND flash memory factory in upstate New York, as reported by Reuters. This potential investment aligns with U.S. government efforts to boost domestic chip manufacturing amid rising global demand for memory supplies due to artificial intelligence infrastructure spending. SK hynix shares rose 1.44% to $185.62 in premarket trading, and the company has not confirmed any specific plans for the factory yet. The factory would help reduce reliance on Solidigm's sole production facility in Dalian, China. https://www.openbell.ai/news/BROS:1789728510557 2026-09-18T10:48:30.557Z daily 0.9 https://cdn.brandfetch.io/BROS/w/400/h/400?c=1idopYfmtR7ZKg8QMud TD Cowen Reiterates Buy on Dutch Bros, Maintains $59 Price Target TD Cowen analyst Andrew M. Charles has reiterated a Buy rating on Dutch Bros (NYSE: BROS) and maintained a price target of $59 for the stock. This endorsement reflects confidence in the company's performance and market position. https://www.openbell.ai/news/EAT:1789728191439 2026-09-18T10:43:11.439Z daily 0.9 https://cdn.brandfetch.io/EAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud TD Cowen Reiterates Buy on Brinker International, Maintains $270 Price Target TD Cowen analyst Andrew M. Charles has reiterated a Buy rating on Brinker International (NYSE: EAT) and maintained a price target of $270 for the stock. This endorsement suggests confidence in the company's performance and potential for growth. https://www.openbell.ai/news/CRWV:1789728057900 2026-09-18T10:40:57.900Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/New-York-City--New-York---July-14-2025-C.jpg?width=250&height=187 CoreWeave Becomes First to Deploy Vera Rubin — Here's What Else Happened This Week CoreWeave Inc. (NASDAQ: CRWV) has made significant advancements this week, including the deployment of a multi-rack NVIDIA Vera Rubin NVL72 cluster for agentic AI workloads and a 15-year data center lease with Blockfusion USA for capacity at its Niagara Falls campus. The company is also planning to raise $3.0 billion through a private offering of convertible senior notes due 2033, with an additional $500 million option. As of the latest data, CoreWeave shares are trading 1.14% higher at $80.79. https://www.openbell.ai/news/CUE:1789727999133 2026-09-18T10:39:59.133Z daily 0.9 https://cdn.brandfetch.io/CUE/w/400/h/400?c=1idopYfmtR7ZKg8QMud B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83 B. Riley Securities has initiated coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating. The analyst, Mayank Mamtani, has set a price target of $83 for the company's stock. https://www.openbell.ai/news/NPCE:1789727897397 2026-09-18T10:38:17.397Z daily 0.9 https://cdn.brandfetch.io/NPCE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18 Keybanc analyst Brett Fishbin has initiated coverage on NeuroPace (NASDAQ: NPCE) with an Overweight rating. The firm has set a price target of $18 for the company's stock. https://www.openbell.ai/news/USAS:1789727796880 2026-09-18T10:36:36.880Z daily 0.9 https://cdn.brandfetch.io/USAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Americas Gold And Silver Announcs High-Grade Ag-Cu-Pb-Sb Drill Results From Its Galena Complex Drilling Program Americas Gold And Silver has reported high-grade drill results from its Galena Complex, including a new vein discovery on the 49 level with 1.2m intersecting 1,061 g/t Ag, 0.7% Cu, and 0.6% Sb. Additionally, the 9 Vein showed a significant intersection of 0.4m at 7,123 g/t Ag, 3.24% Cu, and 1.81% Sb. The 520 Vein system at Coeur has also expanded, now extending 200m along strike and 200m vertically, with further exploration potential identified above the 6,000ft level. https://www.openbell.ai/news/BESS:1789727674522 2026-09-18T10:34:34.522Z daily 0.9 https://cdn.brandfetch.io/BESS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bimergen Energy Emergen Energy Completes Its System For Award Management Registration And Receives Commercial And Government Entity Code Bimergen Energy's subsidiary, Emergen Energy, has completed its System for Award Management (SAM) registration and received a Commercial and Government Entity (CAGE) code, enabling it to compete for federal contracts and pursue federal assistance opportunities. This registration is a key step in Bimergen's strategy to expand its energy storage capabilities and build relationships within the federal marketplace. The company aims to leverage this milestone to enhance its market presence and support its growth strategy focused on reliable energy infrastructure. https://www.openbell.ai/news/DT:1789727668596 2026-09-18T10:34:28.596Z daily 0.9 https://cdn.brandfetch.io/DT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Upgrades Dynatrace to Buy, Announces $68 Price Target Needham analyst Mike Cikos has upgraded Dynatrace (NYSE: DT) from a Hold to a Buy rating. The firm has set a price target of $68 for the stock. https://www.openbell.ai/news/AMD:1789727644858 2026-09-18T10:34:04.858Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Amd-Chip-On-A-Dark--Intricate-Circuit-Bo.jpg?width=250&height=187 AMD Says AI Adoption Is Still Early, Sees No Slowdown in Demand Advanced Micro Devices Inc. (AMD) reported a nearly 1% increase in stock price to $550.25 during premarket trading, following positive remarks from CTO Mark Papermaster regarding ongoing demand for artificial intelligence (AI). Papermaster indicated that while businesses are in the early stages of AI adoption and may become more selective with workloads, overall demand is expected to remain strong. AMD is shifting its focus from individual chips to complete computing systems and plans to introduce AI rack-level integration later this year, aiming to enhance its exposure to AI infrastructure spending. https://www.openbell.ai/news/CDT:1789727583382 2026-09-18T10:33:03.382Z daily 0.9 https://cdn.brandfetch.io/CDT/w/400/h/400?c=1idopYfmtR7ZKg8QMud CDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo CDT Equity Partners has partnered with QIMA Life Sciences to develop autoimmune skin disease assets, focusing on novel combinations of tapinarof (VTAMA®) for psoriasis and vitiligo. Tapinarof is currently approved for plaque psoriasis and atopic dermatitis in the US and Japan, and CDT aims to enhance its efficacy through combination therapies. The global vitiligo drug market is projected to grow from approximately $2.6 billion in 2025 to $6.6 billion by 2030, highlighting a significant opportunity for new therapies in this area. https://www.openbell.ai/news/ETSY:1789727331065 2026-09-18T10:28:51.065Z daily 0.9 https://cdn.brandfetch.io/ETSY/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Upgrades Etsy to Buy, Announces $90 Price Target BTIG analyst Marvin Fong has upgraded Etsy (NYSE: ETSY) from a Neutral rating to a Buy rating. Along with the upgrade, a price target of $90 has been announced for the stock. https://www.openbell.ai/news/BGSI:1789727313623 2026-09-18T10:28:33.623Z daily 0.9 https://cdn.brandfetch.io/BGSI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mizuho Initiates Coverage On Boyd Group Services with Outperform Rating, Announces Price Target of $120 Mizuho analyst David Bellinger has initiated coverage on Boyd Group Services (NYSE: BGSI) with an Outperform rating. The analyst has set a price target of $120 for the company's stock. https://www.openbell.ai/news/SPCX:1789727246222 2026-09-18T10:27:26.222Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Starlink-is-a-satellite-internet-constel.jpg?width=250&height=187 SpaceX Wins FCC Nod for Global Starlink Mobile Services as It Targets 5G Connectivity From Space SpaceX has received FCC approval to provide international telecommunications services through its Starlink Mobile, aiming for direct-to-phone 5G connectivity. The approval allows SpaceX to support Starlink Mobile service offerings, enhancing its ability to carry international traffic as it expands its satellite-to-phone network, which currently includes about 650 satellites and can reach approximately 1.9 billion people. The company is also preparing to launch next-generation Mobile V2 satellites, which are expected to deliver significantly improved throughput and full 5G connectivity. SpaceX's strategic partnerships with telecom operators like T-Mobile US Inc. will further bolster its service capabilities. https://www.openbell.ai/news/HYPG:1789727126841 2026-09-18T10:25:26.841Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Hyperliquid-Logo-And-Coins--3d-Render.jpg?width=250&height=187 Why Is Hyperliquid Stock Surging On Friday? Hyperliquid Strategies Inc (NASDAQ: PURR) shares surged nearly 8% during Friday's premarket session, trading at $13.82, following the SEC's approval of an Innovation Exemption for tokenized U.S. stock trading on public blockchains. This regulatory relief allows Tokenized Securities Venues to trade tokenized stocks while ensuring traditional shareholder rights are maintained. The company's upcoming earnings report is estimated to show a revenue of $9.78 million and an EPS of 12 cents, with analysts giving it a Buy rating and an average price target of $19.80. https://www.openbell.ai/news/FNF:1789727111804 2026-09-18T10:25:11.804Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Financial-chart.jpg?width=250&height=187 Top 3 Financial Stocks That Are Preparing To Pump In Q3 The article highlights three financial stocks that are currently considered oversold, presenting potential buying opportunities. Fidelity National Financial Inc (FNF) has an RSI of 28.8 and a recent stock price of $43.07, down 11% over the past month. Glacier Bancorp Inc (GBCI) has an RSI of 29.6, closing at $44.72 after a 9% decline, while Artisan Partners Asset Management Inc (APAM) has an RSI of 28.9, with shares closing at $36.53 after a 12% drop. All three companies are experiencing significant price declines, indicating potential for recovery. https://www.openbell.ai/news/CRM:1789726877743 2026-09-18T10:21:17.743Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Salesforce-AI-Partnership.jpg?width=250&height=187 Agentforce Triggers Renewal Surge, Sparking Salesforce AI Boom: Analyst Salesforce Inc. (NYSE: CRM) is focusing on expanding its AI monetization strategy, with expectations of revenue reacceleration starting in Q3, as noted by BNP Paribas analyst Stefan Slowinski. The company maintains a fiscal 2030 revenue outlook of $63 billion and is implementing various pricing models for its Agentforce product. Additionally, Salesforce has initiated a $25 billion accelerated share repurchase program, aiming to reduce its share count by over 14%. As of the latest report, Salesforce shares were trading at $243.14, reflecting a 0.12% increase in premarket trading. https://www.openbell.ai/news/EAT:1789726847326 2026-09-18T10:20:47.326Z daily 0.9 https://cdn.brandfetch.io/EAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stephens & Co. Reiterates Overweight on Brinker International, Maintains $300 Price Target Stephens & Co. analyst Jim Salera has reiterated an Overweight rating on Brinker International (NYSE: EAT) and has maintained a price target of $300 for the stock. This endorsement suggests confidence in the company's performance and potential growth. https://www.openbell.ai/news/TRAX:1789726730737 2026-09-18T10:18:50.737Z daily 0.9 https://cdn.brandfetch.io/TRAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65 Evercore ISI Group has initiated coverage on First Tracks (NASDAQ: TRAX) with an Outperform rating. The firm has set a price target of $65 for the company's stock. https://www.openbell.ai/news/GOOG:1789726724889 2026-09-18T10:18:44.889Z daily 0.9 https://cdn.brandfetch.io/GOOG/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Anthropic quietly sets up biology lab as it ramps AI drug program' - Reuters Exclusive Anthropic has established a biology lab to enhance its AI-driven drug development program. This strategic move indicates the company's commitment to expanding its capabilities in the biotechnology sector. The initiative aligns with the growing trend of integrating artificial intelligence into pharmaceutical research and development. https://www.openbell.ai/news/SKHY:1789726647198 2026-09-18T10:17:27.198Z daily 0.9 https://cdn.brandfetch.io/SKHY/w/400/h/400?c=1idopYfmtR7ZKg8QMud SK hynix’s Solidigm Eyes New York for US Chip Factory SK hynix's subsidiary Solidigm is considering establishing a NAND flash memory factory in Upstate New York, as reported by Reuters. This potential investment aligns with U.S. government efforts to boost domestic chip manufacturing amid increasing demand for memory due to artificial intelligence infrastructure spending. SK hynix shares rose 1.44% to $185.62 in premarket trading, and the stock carries a consensus Buy rating with an average price forecast of $247.67.